IONIS-MAPTRx BIIB080; ISIS 814907,94.68%
产品编号:Bellancom-132582| CAS NO:2857842-32-9| 分子量:7182.00
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
IONIS-MAPTRx BIIB080; ISIS 814907
产品介绍 | IONIS-MAPTRx (BIIB080) 是第一个降低 Tau 的反义寡核苷酸 (ASO)。IONIS-MAPTRx具有研究阿尔茨海默病的潜力。( 西域 IONIS-MAPTRx 用于小鼠: TauASO-12 序列 – 5′ GCTTTTACTGACCATGCGAG 3′ ) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease. ( 西域 IONIS-MAPTRx for murine use: TauASO-12 sequence – 5′ GCTTTTACTGACCATGCGAG 3′ ) | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
Intrathecal administrations of IONIS-MAPTRx in nonhuman primates showed a mean MAPT mRNA reduction of 77% in frontal cortex and 74% in hippocampus without dose-limiting side effects. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Intrathecal administrations of IONIS-MAPTRx in nonhuman primates showed a mean MAPT mRNA reduction of 77% in frontal cortex and 74% in hippocampus without dose-limiting side effects. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
H2O : 50 mg/mL (6.96 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |